Fei M, Wen XQ, Yu ZL, Kang T, Wu WH, Ou ST. Roxadustat as treatment for a blood transfusion-dependent maintenance hemodialysis patient: A case report and review of literature. World J Clin Cases 2021; 9(15): 3680-3688 [PMID: 34046470 DOI: 10.12998/wjcc.v9.i15.3680]
Corresponding Author of This Article
San-Tao Ou, MD, PhD, Chief Doctor, Professor, Department of Nephrology, The Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Luzhou 646000, Sichuan Province, China. ousantao@163.com
Research Domain of This Article
Urology & Nephrology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Fei M, Wen XQ, Yu ZL, Kang T, Wu WH, Ou ST. Roxadustat as treatment for a blood transfusion-dependent maintenance hemodialysis patient: A case report and review of literature. World J Clin Cases 2021; 9(15): 3680-3688 [PMID: 34046470 DOI: 10.12998/wjcc.v9.i15.3680]
World J Clin Cases. May 26, 2021; 9(15): 3680-3688 Published online May 26, 2021. doi: 10.12998/wjcc.v9.i15.3680
Roxadustat as treatment for a blood transfusion-dependent maintenance hemodialysis patient: A case report and review of literature
Min Fei, Xiang-Qiong Wen, Zhao-Lan Yu, Ting Kang, Wei-Hua Wu, San-Tao Ou
Min Fei, Xiang-Qiong Wen, Zhao-Lan Yu, Ting Kang, Wei-Hua Wu, San-Tao Ou, Department of Nephrology, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China
Min Fei, Xiang-Qiong Wen, Zhao-Lan Yu, Ting Kang, Wei-Hua Wu, San-Tao Ou, Sichuan Clinical Research Center for Nephropathy, Luzhou 646000, Sichuan Province, China
Author contributions: Ou ST and Wen XQ treated the patient; Yu ZL followed up with the patient and collected the clinical data; Wu WH analyzed and interpreted the clinical data; Fei M wrote the first draft; Kang T and Fei M wrote the final draft; All authors read and approved the final manuscript.
Supported bySichuan Clinical Research Center for Nephropathy, No. 2019YFS0537-3.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: San-Tao Ou, MD, PhD, Chief Doctor, Professor, Department of Nephrology, The Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Luzhou 646000, Sichuan Province, China. ousantao@163.com
Received: December 21, 2020 Peer-review started: December 21, 2020 First decision: January 17, 2021 Revised: January 25, 2021 Accepted: March 15, 2021 Article in press: March 15, 2021 Published online: May 26, 2021 Processing time: 140 Days and 19.6 Hours
Core Tip
Core Tip: Anemia is a common complication of chronic kidney disease, often in combination with increased morbidity and mortality. Treatment of anemia in advanced chronic kidney disease includes iron replacement and administration of erythropoiesis-stimulating agents (ESAs). However, anemia remains undertreated because of concerns of the safety of ESAs. Roxadustat is an oral hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI) that stimulates erythropoiesis and regulates iron metabolism. We present a case in which Roxadustat was used for the treatment of a blood transfusion-dependent maintenance hemodialysis patient. This case highlights that increasing HIF activity with small-molecule HIF-PHIs such as Roxadustat is an innovative therapeutic approach for anemia.
